All News
ACR20 - Day 4 Report
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Read ArticleTofacitinib for Ankylosing Spondylitis
Investigations on the efficacy and safety of JAK inhibitors as a therapeutic option in the management of AS are increasing.
Read ArticleRheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Olga Petryna DrPetryna ( View Tweet)
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr. Antoni Chan synovialjoints ( View Tweet)


